[
  {
    "ts": null,
    "headline": "Merck (MRK) Outpaces Stock Market Gains: What You Should Know",
    "summary": "Merck (MRK) closed the most recent trading day at $86.32, moving +1.8% from the previous trading session.",
    "url": "https://finnhub.io/api/news?id=f688a5a5318f19c4a75673b8d02d8fed9f0b71ff87fbb1156966054005bee0d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760997002,
      "headline": "Merck (MRK) Outpaces Stock Market Gains: What You Should Know",
      "id": 137174224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) closed the most recent trading day at $86.32, moving +1.8% from the previous trading session.",
      "url": "https://finnhub.io/api/news?id=f688a5a5318f19c4a75673b8d02d8fed9f0b71ff87fbb1156966054005bee0d7"
    }
  },
  {
    "ts": null,
    "headline": "Neuphoria Says Phase 3 Trial of BNC210 to Treat Social Anxiety Disorder Did Not Meet Primary Endpoint",
    "summary": "Neuphoria Therapeutics (NEUP) said Monday that a phase 3 trial of BNC210 for the acute treatment of",
    "url": "https://finnhub.io/api/news?id=bb1448244d9d8b1f64fb8cd5dcad68152266d49cbba1fab709440743e46261a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760995135,
      "headline": "Neuphoria Says Phase 3 Trial of BNC210 to Treat Social Anxiety Disorder Did Not Meet Primary Endpoint",
      "id": 137174225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Neuphoria Therapeutics (NEUP) said Monday that a phase 3 trial of BNC210 for the acute treatment of",
      "url": "https://finnhub.io/api/news?id=bb1448244d9d8b1f64fb8cd5dcad68152266d49cbba1fab709440743e46261a9"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan Says Correction Will Be “Healthy” – 5 Safe High-Yield Dividend Stocks",
    "summary": "Jamie Dimon is one of the highest-profile bankers in the world. Like Warren Buffett, David Solomon, or other Wall Street titans, when he speaks, people listen. Recently, the JPMorgan CEO called the three-year bull market run unmistakable, while warning that asset prices are currently high and credit spreads are unusually tight —a rough combination that ... JPMorgan Says Correction Will Be “Healthy” – 5 Safe High-Yield Dividend Stocks",
    "url": "https://finnhub.io/api/news?id=a04cfd4e957b0f21becc5b08e6de5be711350f5c262b2ef2431dd738bdd5b531",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760994750,
      "headline": "JPMorgan Says Correction Will Be “Healthy” – 5 Safe High-Yield Dividend Stocks",
      "id": 137178122,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Jamie Dimon is one of the highest-profile bankers in the world. Like Warren Buffett, David Solomon, or other Wall Street titans, when he speaks, people listen. Recently, the JPMorgan CEO called the three-year bull market run unmistakable, while warning that asset prices are currently high and credit spreads are unusually tight —a rough combination that ... JPMorgan Says Correction Will Be “Healthy” – 5 Safe High-Yield Dividend Stocks",
      "url": "https://finnhub.io/api/news?id=a04cfd4e957b0f21becc5b08e6de5be711350f5c262b2ef2431dd738bdd5b531"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks rose late Monday afternoon, with the NYSE Health Care Index and the Health Care S",
    "url": "https://finnhub.io/api/news?id=1a966a37f9e4935d63e46fb17c585e40cb19ddd881125303a5bcf990872fa352",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760989175,
      "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
      "id": 137174226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Monday afternoon, with the NYSE Health Care Index and the Health Care S",
      "url": "https://finnhub.io/api/news?id=1a966a37f9e4935d63e46fb17c585e40cb19ddd881125303a5bcf990872fa352"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Monday Afternoon",
    "summary": "Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.9% and the Health Car",
    "url": "https://finnhub.io/api/news?id=66d5a95ef6731ccf6f4aa87317fee196715bc369b42918ac99cb391528d060a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760983186,
      "headline": "Sector Update: Health Care Stocks Advance Monday Afternoon",
      "id": 137174227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.9% and the Health Car",
      "url": "https://finnhub.io/api/news?id=66d5a95ef6731ccf6f4aa87317fee196715bc369b42918ac99cb391528d060a6"
    }
  },
  {
    "ts": null,
    "headline": "Neuphoria Conducting Strategic Review After Anti-Anxiety Drug Trial Misses Endpoint",
    "summary": "Neuphoria Conducting Strategic Review After Anti-Anxiety Drug Trial Misses Endpoint",
    "url": "https://finnhub.io/api/news?id=3f4035ec8ee127928f251e556618ffa9a149037944b910e96856edda2ef748e6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760979780,
      "headline": "Neuphoria Conducting Strategic Review After Anti-Anxiety Drug Trial Misses Endpoint",
      "id": 137226341,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Neuphoria Conducting Strategic Review After Anti-Anxiety Drug Trial Misses Endpoint",
      "url": "https://finnhub.io/api/news?id=3f4035ec8ee127928f251e556618ffa9a149037944b910e96856edda2ef748e6"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Reveals Sectors With Top 2026 Payouts: 5 Strong Buys",
    "summary": "These five Goldman Sachs stock picks are poised for growth in 2026 and will continue to pay and raise their already significant and reliable dividends.",
    "url": "https://finnhub.io/api/news?id=aaaac0159c394173a6381c75376ceaf8152836ead531cdbe2f228823f7c7d8c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760977003,
      "headline": "Goldman Sachs Reveals Sectors With Top 2026 Payouts: 5 Strong Buys",
      "id": 137177938,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "These five Goldman Sachs stock picks are poised for growth in 2026 and will continue to pay and raise their already significant and reliable dividends.",
      "url": "https://finnhub.io/api/news?id=aaaac0159c394173a6381c75376ceaf8152836ead531cdbe2f228823f7c7d8c1"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Apple iPhone 17 Outsells Predecessor in US, China in First 10 Days; Amazon Web Services Outage Impacts Apps, Websites it Hosts",
    "summary": "All three major US stock indexes were up in midday trading Monday ahead of big-name earnings this we",
    "url": "https://finnhub.io/api/news?id=ea73f923ac26e7911d197e738ad840103c92982a490c1b7766fe9a2aedff34e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760976686,
      "headline": "Top Midday Stories: Apple iPhone 17 Outsells Predecessor in US, China in First 10 Days; Amazon Web Services Outage Impacts Apps, Websites it Hosts",
      "id": 137173950,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up in midday trading Monday ahead of big-name earnings this we",
      "url": "https://finnhub.io/api/news?id=ea73f923ac26e7911d197e738ad840103c92982a490c1b7766fe9a2aedff34e4"
    }
  },
  {
    "ts": null,
    "headline": "Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings",
    "summary": "ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.",
    "url": "https://finnhub.io/api/news?id=1e9dbaf41953c277f26e4ff578a8861bfff09a0cdfb19eb428566cf3bedcc0c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760969400,
      "headline": "Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings",
      "id": 137174096,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.",
      "url": "https://finnhub.io/api/news?id=1e9dbaf41953c277f26e4ff578a8861bfff09a0cdfb19eb428566cf3bedcc0c4"
    }
  },
  {
    "ts": null,
    "headline": "Dow rallies 550 points on gains for shares of Salesforce, Apple",
    "summary": "Dow rallies 550 points on gains for shares of Salesforce, Apple",
    "url": "https://finnhub.io/api/news?id=91a312f31ebd1be67cda5de25f3781b36cdaafda4941d0b06208b3fb7769a909",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760969040,
      "headline": "Dow rallies 550 points on gains for shares of Salesforce, Apple",
      "id": 137225678,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow rallies 550 points on gains for shares of Salesforce, Apple",
      "url": "https://finnhub.io/api/news?id=91a312f31ebd1be67cda5de25f3781b36cdaafda4941d0b06208b3fb7769a909"
    }
  },
  {
    "ts": null,
    "headline": "2 Beaten-Down Stocks to Buy and Hold for the Next Decade",
    "summary": "That's plenty of time for these drugmakers to move past their challenges.",
    "url": "https://finnhub.io/api/news?id=4738c2f8f69ee04d14ad7e72ad29e51a1ddbea2f8e4796e32eb9fdd019be6818",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760965620,
      "headline": "2 Beaten-Down Stocks to Buy and Hold for the Next Decade",
      "id": 137174230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "That's plenty of time for these drugmakers to move past their challenges.",
      "url": "https://finnhub.io/api/news?id=4738c2f8f69ee04d14ad7e72ad29e51a1ddbea2f8e4796e32eb9fdd019be6818"
    }
  },
  {
    "ts": null,
    "headline": "KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)",
    "summary": "RAHWAY, N.J., October 20, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in treating non-small cell lung cancer (NSCLC). The results are based on the exploratory five-year analyses of KEYNOTE-671 evaluating KEYTRUDA as part of a neoadjuvant followed by adjuvant (perioperative) treatment regimen for patients with resectable NSCLC;",
    "url": "https://finnhub.io/api/news?id=5d64c1902c4bb9641360a9e53f75f9d97594b9bc89f6e0e646459d9bca90e7c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760964300,
      "headline": "KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)",
      "id": 137174231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 20, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in treating non-small cell lung cancer (NSCLC). The results are based on the exploratory five-year analyses of KEYNOTE-671 evaluating KEYTRUDA as part of a neoadjuvant followed by adjuvant (perioperative) treatment regimen for patients with resectable NSCLC;",
      "url": "https://finnhub.io/api/news?id=5d64c1902c4bb9641360a9e53f75f9d97594b9bc89f6e0e646459d9bca90e7c6"
    }
  },
  {
    "ts": null,
    "headline": "My Top 3 Pharma Stocks",
    "summary": "Discover the top 3 Big Pharma stocks beating forecasts and offering high dividends.",
    "url": "https://finnhub.io/api/news?id=16b7d42a7ab56fff4cf263eccf8bc6b046116accec4a8334c5f7f3ce0f4d8cee",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760960303,
      "headline": "My Top 3 Pharma Stocks",
      "id": 137168226,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1039670620/image_1039670620.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover the top 3 Big Pharma stocks beating forecasts and offering high dividends.",
      "url": "https://finnhub.io/api/news?id=16b7d42a7ab56fff4cf263eccf8bc6b046116accec4a8334c5f7f3ce0f4d8cee"
    }
  },
  {
    "ts": null,
    "headline": "Merck breaks ground on $3B manufacturing plant in Virginia",
    "summary": "Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion U.S. investment strategy.",
    "url": "https://finnhub.io/api/news?id=c0955f7fd4bf72934bbb821f492980ac23af046e2e1d07ac13f2f48191d3c169",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760957338,
      "headline": "Merck breaks ground on $3B manufacturing plant in Virginia",
      "id": 137174232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion U.S. investment strategy.",
      "url": "https://finnhub.io/api/news?id=c0955f7fd4bf72934bbb821f492980ac23af046e2e1d07ac13f2f48191d3c169"
    }
  },
  {
    "ts": null,
    "headline": "Salesforce, Apple share gains lead Dow's nearly 425-point jump",
    "summary": "Salesforce, Apple share gains lead Dow's nearly 425-point jump",
    "url": "https://finnhub.io/api/news?id=19520a4ededae27f7cb8db14766a24cb98829964b67a3ca16aa1a702f94eb031",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760957160,
      "headline": "Salesforce, Apple share gains lead Dow's nearly 425-point jump",
      "id": 137225679,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Salesforce, Apple share gains lead Dow's nearly 425-point jump",
      "url": "https://finnhub.io/api/news?id=19520a4ededae27f7cb8db14766a24cb98829964b67a3ca16aa1a702f94eb031"
    }
  },
  {
    "ts": null,
    "headline": "Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia",
    "summary": "RAHWAY, N.J., October 20, 2025--Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia",
    "url": "https://finnhub.io/api/news?id=8200ed1ecb704665826ef7916109739c731368aa4c08c570ade382eab9b75ec9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760957100,
      "headline": "Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia",
      "id": 137174233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 20, 2025--Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia",
      "url": "https://finnhub.io/api/news?id=8200ed1ecb704665826ef7916109739c731368aa4c08c570ade382eab9b75ec9"
    }
  },
  {
    "ts": null,
    "headline": "IXJ: Healthcare Sector Dashboard For October",
    "summary": "Healthcare providers and pharmaceuticals/biotechnology subsectors are undervalued versus 11-year averages, with pharma/biotech also showing strong quality metrics. Read the full analysis.",
    "url": "https://finnhub.io/api/news?id=7e5e4d81e7f7bbf4ace2094dc8b479304205e7043756c5390b7cef95e12da826",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760955567,
      "headline": "IXJ: Healthcare Sector Dashboard For October",
      "id": 137167977,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1409850701/image_1409850701.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Healthcare providers and pharmaceuticals/biotechnology subsectors are undervalued versus 11-year averages, with pharma/biotech also showing strong quality metrics. Read the full analysis.",
      "url": "https://finnhub.io/api/news?id=7e5e4d81e7f7bbf4ace2094dc8b479304205e7043756c5390b7cef95e12da826"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 250-point rally led by gains in Apple, Salesforce shares",
    "summary": "Dow's 250-point rally led by gains in Apple, Salesforce shares",
    "url": "https://finnhub.io/api/news?id=993edd1ea0ed5db5d3a3296bbdfd2e9fd88d8237d41eb8ce66a45e2bc2ee7a60",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760953500,
      "headline": "Dow's 250-point rally led by gains in Apple, Salesforce shares",
      "id": 137225680,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow's 250-point rally led by gains in Apple, Salesforce shares",
      "url": "https://finnhub.io/api/news?id=993edd1ea0ed5db5d3a3296bbdfd2e9fd88d8237d41eb8ce66a45e2bc2ee7a60"
    }
  },
  {
    "ts": null,
    "headline": "Summit’s dual-acting drug scores lung cancer win",
    "summary": "A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study that could reshape first-line treatment regimens.",
    "url": "https://finnhub.io/api/news?id=aeaad502b8688f719dd82dcca1201823a07459fe4b7561629036574b7439c6a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760951607,
      "headline": "Summit’s dual-acting drug scores lung cancer win",
      "id": 137174234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study that could reshape first-line treatment regimens.",
      "url": "https://finnhub.io/api/news?id=aeaad502b8688f719dd82dcca1201823a07459fe4b7561629036574b7439c6a7"
    }
  },
  {
    "ts": null,
    "headline": "Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors",
    "summary": "BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy LUND, ...",
    "url": "https://finnhub.io/api/news?id=4cd90b68fb7bcff62441859b49ee02348a1e54db9557bb8e071ae02d2f605df4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760943000,
      "headline": "Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors",
      "id": 137168768,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy LUND, ...",
      "url": "https://finnhub.io/api/news?id=4cd90b68fb7bcff62441859b49ee02348a1e54db9557bb8e071ae02d2f605df4"
    }
  },
  {
    "ts": null,
    "headline": "Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors",
    "summary": "BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy Strasbourg, France, and Lund, Sweden, October 20, 2025, 08:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (N",
    "url": "https://finnhub.io/api/news?id=ba22e8770738d8cc3cf09e5a98ba33368fc110c7264b019a8b1615c22dd43cfb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760941800,
      "headline": "Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors",
      "id": 137164363,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy Strasbourg, France, and Lund, Sweden, October 20, 2025, 08:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (N",
      "url": "https://finnhub.io/api/news?id=ba22e8770738d8cc3cf09e5a98ba33368fc110c7264b019a8b1615c22dd43cfb"
    }
  },
  {
    "ts": null,
    "headline": "IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025",
    "summary": "Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistical significance Improvement in PFS favored the combination across virtually all subgroups, notably in patients with PD-L1-negative tumors, BRAFV600-mutated tumors, and elevated LDH, without adding any systemic toxicity compared to pembrolizumab alone",
    "url": "https://finnhub.io/api/news?id=096f8f797707df7013cc93bcdf7b1f67df49521ee2aa093aeb1ab206db379e90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760941800,
      "headline": "IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025",
      "id": 137164362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistical significance Improvement in PFS favored the combination across virtually all subgroups, notably in patients with PD-L1-negative tumors, BRAFV600-mutated tumors, and elevated LDH, without adding any systemic toxicity compared to pembrolizumab alone",
      "url": "https://finnhub.io/api/news?id=096f8f797707df7013cc93bcdf7b1f67df49521ee2aa093aeb1ab206db379e90"
    }
  }
]